All In Biotech

Drug Trial Radar · NCT05478720

DON in Pediatric Cerebral Malaria

DON in Pediatric Cerebral Malaria: A Phase I/IIa Dose-Escalation Safety Study

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Aug 16, 2022

Primary completion

Nov 30, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Douglas Postels, MD, MSNot stated
Sponsor type
Not stated
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are: * Evaluate the safety of a single intravenous dose of DON in healthy adults and adults with uncomplicated malaria ( Part 1) * Determine the safety of a single dose of DON in children 12 months-14 years old with World Health Organization (WHO) clinically defined CM (Part 2 :Cohort 1-4) * Determine the pharmacokinetic (PK) profile of a single dose of DON in healthy adults, adults with uncomplicated malaria and children with CM (Part 1, and Cohorts 1-4 of Part 2) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with improved intracerebral blood flow dynamics on transcranial doppler (TCD) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with a reduction in brain volume score on magnetic resonance imaging (MRI) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with cerebral malaria is associated with changes in electroencephalogram (EEG) pattern (Part 2 :Cohort 1-4) * Exploratory: Explore the metabolic mechanisms of action of adjunctive DON in children with CM Healthy adult participants will receive: * anti-emetic ondansetron * one dose of DON Adults with uncomplicated malaria will receive: * anti-emetic ondansetron * one dose of DON * artemisinin-combination therapies per Malawi Ministry of Health guidelines Pediatric participants will receive: * one dose of DON * anti-emetic ondansetron and per Malawi Ministry of Health guidelines: * enteral lumefantrine-artemether therapy, and * artesunate therapy

Conditions

  • Malaria, Cerebral

Interventions

  • 6-diazo-5-oxo-L-norleucine (DON)Drug

    Single intravenous dose ranging from 0.1-10 mg/kg per dose

  • PlaceboDrug

    Single intravenous dose of saline

  • 6-diazo-5-oxo-L-norleucine (DON)Drug

    Single intravenous dose ranging from 0.1-1.0 mg/kg per dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of local AEs occurring within 14 days after the administration of DONTime frame: 14 days
  2. Incidence of systemic AEs occurring within 14 days after the administration of DONTime frame: 14 days
  3. Incidence of systemic SAEs occurring within 14 days after the administration of DONTime frame: 14 days
  4. Assessment of Blantyre Coma ScoreTime frame: 14 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Ndirande Research Clinic

    Blantyre, Malawi · Completed

  • Queen Elizabeth Central Hospital

    Blantyre, Malawi · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.